Alternative Treatment Options for Older Patients With AML
10/23/2019
In a debate at the 2019 Lymphoma & Myeloma Congress, Sangmin Lee, MD, Weill Cornell Medicine and New, New York, NY, argued that venetoclax combined with azacitidine, decitabine, and LDAC, should not be the new standard of care for AML patients aged ≥60 years.